RecruitingPhase 1Phase 2NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
Sponsor
Daiichi Sankyo
Enrollment
590 participants
Start Date
Aug 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called DS-3939a for people with advanced solid tumor and metastatic solid tumor. The study is currently recruiting participants at 33 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDS-3939a
One IV infusion Q3W on Day 1 of each 21-day cycle
Locations(33)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05875168
Related Trials
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT0683300813 locations
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT0721383011 locations
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
NCT076694151 location
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT0526762618 locations
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
NCT0721381712 locations